Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019

By sjmartinez • March 18, 2025

Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga A, Jensen TO, Jain MK, Kalomenidis I, Kim K, Lallemand P, Lindegaard B, Menon A, Ognenovska K, Poulakou G, Thorup Røge B, Rogers AJ, Shaw-Saliba K, Sandkovsky U, Trautner BW, Vasudeva SS, Vekstein A, Viens K, Wyncoll J, DuChateau B, Zhang Z, Wu S, Babiker AG, Davey V, Gelijns A, Higgs E, Kan V, Lundgren J, Matthews GV, Lane HC. Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019. J Infect Dis. 2025 Mar 17;231(3):677-683. doi: 10.1093/infdis/jiae452. PMID: 39269490; PMCID: PMC11911911.

Tags: antibody tests, biomarkers, covid-19, Harbor UCLA, Infectious Diseases, personalized medicine, point-of-care tests, Publications

Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavò S, Dischinger U, Dobri GA, Donegan DM, Elenkova A, Fazeli PK, Feelders RA, Garcia-Centeno[...]

A Review of Patient-Reported Outcomes and Clinical Outcomes in Acute and Chronic Myeloid and Lymphoid Leukemias

Chan B, Balar E, Villalona S, Karp J, Leahy A, Lai C. A Review of Patient-Reported Outcomes and Clinical Outcomes in Acute and Chronic Myeloid[...]

Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis

Razavi AC, Bhatia HS, Marrero N, Dzaye O, Post WS, Nasir K, Tsai M, Vaccarino V, Vasan RS, Thanassoulis G, Tsimikas S, Sperling LS, Budoff[...]